GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (LTS:0RCQ) » Definitions » Cash From Other Investing Activities

Nicox (LTS:0RCQ) Cash From Other Investing Activities : €0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Nicox Cash From Other Investing Activities?

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Nicox's cash from other investing activities for the six months ended in Jun. 2024 was €0.00 Mil. It means Nicox received €0.00 Mil from other investing activities. Nicox's cash from other investing activities for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

Nicox Cash From Other Investing Activities Historical Data

The historical data trend for Nicox's Cash From Other Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Cash From Other Investing Activities Chart

Nicox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash From Other Investing Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.17 0.17 -

Nicox Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash From Other Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.14 - - -

Nicox Cash From Other Investing Activities Calculation

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cash From Other Investing Activities for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nicox Cash From Other Investing Activities Related Terms

Thank you for viewing the detailed overview of Nicox's Cash From Other Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (LTS:0RCQ) » Definitions » Cash From Other Investing Activities
Comparable Companies
XPAR:ALPAT XPAR:POXEL XPAR:ALVIO XPAR:ALOPM XPAR:ALNFL XPAR:ALVAL XPAR:ALTME XPAR:ALQGC XPAR:ALTAO XPAR:ALACT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
NICXF:USA ALCOX:France NXOA:Germany NXOA:Germany
Address
Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Website
https://www.nicox.com
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines